surmount-1 tirzepatide weight loss percent nejm 2022 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants Effects of Tirzepatide on the
Pay in 4 interest-free payments of $6.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27















![Trulicity Lawsuit [2026]](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Trulicity-Lawsuit-Other-Drugs-and-Manufacturers-Named-in-the-GLP-1-Lawsuits-1.jpg)












